Over the last few decades, the incidence of fungal infections in humans has increased, especially in patients requiring intensive care. The Extended Prevalence of Infection in Intensive Care study demonstrated that *Candi-da*spp accounted for 18.5% of microorganisms isolated from intensive care unit (ICU) patients in both Western and Eastern Europe ([@B31]). Invasive candidiasis and candidaemia, caused most commonly by *Candida albicans* and *Candida glabrata*, are of growing concern in the ICU ([@B17], [@B22], [@B25]). Polish surveillance involving 94 units in 20 hospitals (including surgery, intensive care, neonatology, haematology and others) indicated that the highest degree of candidaemia was found in the ICU (30.8%) ([@B20]).

Furthermore, *C. albicans* and *C. glabrata* bloodstream infections have been associated with a high mortality rate ([@B33]). Risk factors for invasive fungal infection in ICU patients include the use of broad-spectrum antibacterial agents and immunosuppressive agents, parenteral nutrition, central venous catheters and mechanical ventilations. Immune status, comorbid diseases and the age of patients also contribute to the incidence of fungal diseases ([@B14], [@B2]). Although the most cases of *Candida*infections appear to originate from an endogenous source, there are cases of nosocomial transmission ([@B32], [@B4]). Identification of relatedness between *Candida*species is crucial for control measures to reduce the incidence of nosocomial candidiasis, but little is known of the epidemiology of these species in southern Poland. For this purpose, it is important to perform genotyping analysis that would allow evaluation of the spread of these pathogens. The most commonly used molecular typing methods are restriction endonuclease analysis, microsatellite analysis, multilocus enzyme electrophoresis, pulsed-field gel electrophoresis, multilocus sequence typing and random amplified polymorphic DNA polymerase chain reaction (RAPD PCR) ([@B13], [@B1], [@B11]). The latter method was used in this study to evaluate the level of genetic diversity of *C. albicans* and *C. glabrata* strains isolated from ICU patients from the tertiary hospital in Krakow, Poland over a two-year period.

SUBJECTS, MATERIALS AND METHODS
===============================

*Patients and isolates* - A total of 136 and 145 yeast strains were isolated from patients hospitalised in the ICU of the Rydygier's Specialized Hospital in Krakow in 2011 and 2012, respectively. The species distribution is shown in [Table I](#t01){ref-type="table"}. The predominant species were *C. albicans* (162 strains) and *C. glabrata* (45 strains), obtained from endotracheal aspirates (ETA) and urine. Among the most frequently isolated species, subjected to further molecular studies, were 48 strains, including 31 *C. albicans* and 17 *C. glabrata* isolates cultured at concentrations of ≥ 10^4^ colony-forming unit (cfu)/mL. Of the study group patients, 20 were female, 22 were male and the age range was 19-94 (mean 65) years. In 2011, there were 13 recovered*C. albicans* isolates and seven recovered*C. glabrata* isolates, whereas in 2012 there were 18 *C. albicans* and 10 *C. glabrata* isolated strains, respectively. Twenty nine strains of *C. albicans* and 17 strains of *C. glabrata* were isolated from ETA, while two *C. albicans* isolates were taken from urine. All strains were obtained once per patient, except for *C. albicans*CA11 and CA12 strains, which were isolated from the ETA and urine of the same patient. From five of the patients tested, both *C. albicans*and *C. glabrata* were cultured ([Table II](#t02){ref-type="table"}). Antifungal prophylaxis was not administered to the patients included in this study. This research was approved by the Ethical Committee of Jagiellonian University Medical College (protocol KBET/129/B/2011).

TABLE IYeast species isolated from the intensive care unit patients of the Rydygier's Specialized Hospital in Krakow, Poland, between 2011-2012Yeast speciesYear of isolation  20112012n (%)n (%)*Candida albicans*76 (55.9)86 (59.3)*Candida glabrata*23 (16.9)22 (15.2)*Candida tropicalis*11 (8.1)8 (5.5)*Candida krusei*5 (3.7)8 (5.5)*Candida kefyr*4 (2.9)6 (4.1)*Candida dubliniensis*3 (2.2)2 (1.4)*Candida parapsilosis*3 (2.2)6 (4.1)Other^*a*^11 (8.1)7 (4.8)Total136 (100)145 (100)[^1]

TABLE IIDescription of 31 *Candida albicans* and 17 *Candida glabrata* isolates comprising gender and age of patients, date of isolation, clinical sample, antifungal agents minimal inhibitory concentration (MIC) values and results of random amplified polymorphic DNA polymerase chain reaction (RAPD) analysisIsolate codePatient codeGenderAgeDate of isolationClinical sampleMIC values (mg/L)RAPD profileRAPD clusterAMBFLC5FCVRCCA1SEF7812 Jan 2011ETA14≤ 1≤ 0.12AACA2DMM2516 Mar 2011ETA1≤ 1≤ 1≤ 0.12U1UCA3WMM8030 May 2011ETA0.5≤ 1≤ 1≤ 0.12RRCA4BLM5307 Jun 2011ETA0.5≤ 1≤ 1≤ 0.12DDCA5PAM5018 Aug 2011ETA0.5≤ 1≤ 1≤ 0.12NNCA6LPM2805 Sep 2011ETA0.5≤ 1≤ 1≤ 0.12K1KCA7KLM2821 Sep 2011Urine0.5≤ 1≤ 1≤ 0.12O1OCA8PBF4322 Sep 2011ETA0.5≤ 1≤ 1≤ 0.12O2OCA9SRM3805 Oct 2011ETA0.5≤ 1≤ 1≤ 0.12K2KCA10SLM9007 Oct 2011ETA0.5≤ 1≤ 1≤ 0.12LLCA11BMF6615 Nov 2011ETA1≤ 1≤ 1≤ 0.12PPCA12BMF6616 Nov 2011Urine1≤ 1≤ 1≤ 0.12M1MCA13LFM9029 Dec 2011ETA0.5≤ 1≤ 1≤ 0.12M2MCA14WHM3403 Jan 2012ETA0.5≤ 1≤ 1≤ 0.12CCCA15BuMF5312 Jan 2012ETA1≤ 1≤ 1≤ 0.12E1ECA16PZM8709 Mar 2012ETA1≤ 1≤ 1≤ 0.12T1TCA17ZWM8304 Apr 2012ETA0.5≤ 1≤ 1≤ 0.12E2ECA18KTM6104 Apr 2012ETA0.5≤ 1≤ 1≤ 0.12FFCA19NAF6116 Apr 2012ETA0.5≤ 1≤ 1≤ 0.12E4ECA20ZJF6808 Oct 2012ETA0.5≤ 1≤ 1≤ 0.12J1JCA21OJM6908 Oct 2012ETA0.5≤ 1≤ 1≤ 0.12T2TCA22PPM1910 Oct 2012ETA0.5≤ 1≤ 1≤ 0.12E3ECA23NNF4112 Oct 2012ETA0.5≤ 1≤ 1≤ 0.12J2JCA24OAF4517 Oct 2012ETA≤ 0.25≤ 1≤ 1≤ 0.12GGCA25MRM8612 Nov 2012ETA≤ 0.254≤ 1≤ 0.12U2UCA26TPM5726 Nov 2012ETA0.5≤ 1≤ 1≤ 0.12H1HCA27ZaJF7928 Nov 2012ETA0.5≤ 1≤ 1≤ 0.12H2HCA28ZSF9428 Nov 2012ETA0.5≤ 1≤ 1≤ 0.12SSCA29KMF7618 Dec 2012ETA0.5≤ 1≤ 1≤ 0.12I1ICA30CMF6924 Dec 2012ETA≤ 0.25≤ 1≤ 1≤ 0.12BBCA31KHF6228 Dec 2012ETA0.5≤ 1≤ 1≤ 0.12I2ICG1SZF8028 Apr 2011ETA≤ 0.258≤ 1≤ 0.12aaCG2WMM8030 May 2011ETA0.54≤ 10.25f1fCG3PJM8015 Jun 2011ETA18≤ 1≤ 0.12g1gCG4WJF4729 Jun 2011ETA0.58≤ 1≤ 0.12hhCG5CAM5716 Sep 2011ETA18≤ 1≤ 0.12g2gCG6SLM9007 Oct 2011ETA14≤ 1≤ 0.12iiCG7SJM7028 Oct 2011ETA0.532≤ 1≤ 0.12f2fCG8WEF3731 Jan 2012ETA18≤ 11e2eCG9PZM8704 Apr 2012ETA0.54≤ 10.25d1dCG10LGF7218 Apr 2012ETA14≤ 1≤ 0.12d1dCG11JJM5707 Aug 2012ETA0.54≤ 1≤ 0.12e1eCG12BGF7708 Aug 2012ETA0.58≤ 1≤ 0.12ccCG13ZJF6804 Oct 2012ETA0.52≤ 1≤ 0.12d3dCG14OJM6905 Oct 2012ETA12≤ 1≤ 0.12d2dCG15GGF7825 Oct 2012ETA≤ 0.252≤ 1≤ 0.12d4dCG16GHF8718 Dec 2012ETA0.52≤ 1≤ 0.12jjCG17CMF6924 Dec 2012ETA0.58≤ 1≤ 0.12bb[^2]

*Identification and antifungal susceptibility testing of Candida strains* - All analysed clinical specimens, from ETA (46) and urine (2), were cultured by quantitative technique on Sabouraud dextrose agar (bioMérieux, Poland) and incubated at 37ºC for 48 h. Fungal concentrations between 10^4^ cfu/mL and 10^6^cfu/mL for ETA and 10^5^cfu/mL for urine were observed after 48 h of incubation ([@B18]).

Preliminary fungal strain identification was based on colony morphology on CHROMAgar*Candida* (bioMérieux), while the identification to the species level was confirmed by the Vitek 2 Compact automatic system (bioMérieux). Susceptibility of strains to amphotericin B, fluconazole, 5-fluorocytosine and voriconazole was determined by using the Vitek 2 Compact with AST-YS01 cards and by interpreting results according to the Clinical and Laboratory Standards Institute criteria ([@B7]).

*DNA extraction* - Fungal genomic DNA was extracted with a Genomic Mini AX YEAST isolation kit (A&A Biotechnology, Poland) according to the manufacturer's instructions. Evaluation of the DNA concentration and purity was performed by spectrophotometry at 260 nm and the ratio of the absorbance at 260 nm and 280 nm, respectively. The total genomic DNA was stored at -20ºC for further molecular studies.

*RAPD reaction* - Five arbitrary primers were used for RAPD analysis of *C. albicans* and *C. glabrata* strains: CD16AS (5'-CTCTTGAAACTGGGGAGACTTGA-3'), HP1247 (5'-AAGAGCCCGT-3'), ERIC-2 (5'-AAGTAAGTGACTGGGGTGAGCG-3') ([@B30]), OPE-3 (5'-CCAGATGCAC-3') and OPE-18 (5'-GGACTGCAGA-3') ([@B16]) (Blirt, Poland). The RAPD reactions were performed with 25 ng of *Candida* genomic DNA in a final volume of 25 μL containing 100 pmol of primer (Blirt, Poland), 100 μM of each nucleotide (Fermentas, Lithuania), 0.75 mM MgCl~2~, 0.625 U of GoTaq DNA Polymerase in 5 μL and 5x colourless GoTaq Flexi Buffer (pH 8.5) provided by the manufacturer (Promega, USA). Amplification was carried out in a thermocycler T personal (Biometra, Germany) with an initial denaturation at 95ºC for 2 min followed by 40 cycles of denaturation at 95ºC for 1 min, annealing at 47ºC for 1 min, elongation at 72ºC for 2 min and a final extension at 72ºC for 5 min. The DNA fragments were then separated by 2% agarose gel electrophoresis and visualised by ethidium bromide staining (Sigma-Aldrich, Germany). The PCR product size was determined by comparison with a molecular weight standard (O'Gene Ruler 100 bp DNA Ladder Plus; Thermo Scientific, USA).

The analyses of the genetic relatedness of the *Candi-da*isolates were performed by Bio 1D++ software (Vilber-Lormat, France) via unweighted pair-group method with arithmetic averages using the Dice coefficient. When the similarity value was 100%, the strains were determined to be identical, while isolates with values ranging between 80-99% were considered related and those with values under 80% were considered unrelated. The experiments were carried out in duplicate and there were no differences in the RAPD profiles.

RESULTS
=======

The minimal inhibitory concentration (MIC) values for amphotericin B, fluconazole, 5-fluorocytosine and voriconazole for all tested isolates are shown in the [Table II](#t02){ref-type="table"}. Forty-seven *Candida*strains were susceptible to the antifungal agents tested in this study, except for one *C. glabrata* strain (CG7) that had intermediate susceptibility to fluconazole (MIC 32 mg/L).

Genetic diversity of 31 *C. albicans* and 17 *C. glabrata* isolates were examined in this study. *C. albicans* isolates displayed from one to nine; two-nine, four-nine, four-10 and three-13 bands for OPE-18, HP1247, OPE-3, CD16AS and ERIC-2 primers, respectively. The RAPD patterns obtained for *C. glabrata* were composed of one-five, one-eight, two-10, six-11 and three-12 DNA fragments for HP1247, CD16AS, ERIC-2, OPE-3 and OPE-18 oligonucleotides, respectively. The results of the RAPD reactions obtained with five primers were used for the construction of dendrograms.

Among 31 *C. albicans* strains, 31 RAPD profiles were distinguished. Twenty *C. albicans* isolates were allocated into nine clusters (E, H-K, M, O, T, U) with homology levels higher than 80%, whereas the remaining 11 genotypes (A-D, F, G, L, N, P, R, S) were represented by single isolates only. Four isolates belonged to cluster E, while clusters H-K, M, O, T and U consisted of two strains each ([Fig. 1](#f01){ref-type="fig"}).

Fig. 1: dendrogram presenting the genetic relatedness of 31 *Candida albicans* strains from intensive care unit patients generated by random amplified polymorphic DNA polymerase chain reaction, using CD16AS, HP1247, ERIC-2, OPE-3 and OPE-18 primers. The vertical line divides the strains according to the level of genetic similarity into related and unrelated.

The strains CA11 and CA12, cultured from ETA and urine of the same patient, were unrelated with homology levels under 80%. Two pairs of isolates, CA17-CA22 (cluster E) and CA29-CA31 (cluster I) showed the highest degree of similarity with 94% and 90% homology, respectively. None of the *C. albicans* isolates revealed the same RAPD profile when results from all primers were combined to generate the dendrogram ([Fig. 1](#f01){ref-type="fig"}, [Table II](#t02){ref-type="table"}).

Sixteen patterns were observed in the RAPD analysis of the 17 *C. glabrata* strains. When 80% homology was used as a cut-off point, the *C. glabrata* strains were allocated into four genetic similarity groups (d-g) and six unique profiles were distinguished (a-c, h-j) ([Fig. 2](#f02){ref-type="fig"}). The cluster d comprised of five isolates that presented four different patterns, whereas the remaining four clusters, e-g, contained two isolates each. Among the *C. glabrata* strains, only two isolates, CG9 and CG10 (d1), were identical. Both of them were collected in April 2012 from two patients hospitalised in the ICU. Despite 100% homology, they presented different MIC values to the antifungal agents amphotericin B (MIC 0.5 and 1 mg/L) and voriconazole (MIC 0.25 and ≤ 0.12 mg/L) ([Table II](#t02){ref-type="table"}). The analysis of the dendrogram revealed three groups of isolates: CG8 and CG11 (cluster e), CG9, CG10 and CG14 (cluster d), CG13 and CG15 (cluster d), with 97%, 91% and 90% homology, respectively.

Fig. 2: dendrogram presenting the genetic similarity among 17 *Candida glabrata* strains generated by random amplified polymorphic DNA polymerase chain reaction, using CD16AS, HP1247, ERIC-2, OPE-3 and OPE-18 primers. The vertical line divides the strains according to the level of genetic similarity into related and unrelated.

The discriminatory power (DP) of the RAPD method was calculated for each species according to the Simpson index ([@B10]). When all tested oligonucleotides were combined, the DP value was 1 for *C. albicans* and 0.99 for *C. glabrata*.

DISCUSSION
==========

*C. albicans* is an important cause of nosocomial infections; however, in the last decade, non-*albicans* species were responsible for an increasing number of infections ([@B3], [@B20]). Yeasts are members of the normal microflora of the skin, mucous membranes and gastrointestinal tract in healthy individuals. However, as opportunistic pathogens, they may also cause endogenous infections in immunocompromised patients. Exogenous *Candida* infections are observed less frequently ([@B3], [@B5]). Knowing the source of infection and detection of possible routes of transmission can help with the prevention of clonal spread of pathogenic fungi. RAPD is one of the most frequently used genotyping methods for epidemiological investigations of *Candida* infections worldwide ([@B15], [@B16], [@B19], [@B11]). This technique is easy to perform as well as rapid, cost-effective and suitable for the typing of a large number of strains ([@B21]). RAPD may result in low interlaboratory reproducibility, nevertheless this technique can be applied for the investigation of *Candida*epidemiology on a local level ([@B26]).

In our study, we performed RAPD reactions to evaluate the genetic relatedness of *C. albicans*and *C. glabrata* isolates from southern Poland. We noted a high DP of the RAPD technique. This fact has also been supported by other investigators who reported that RAPD was able to clearly distinguish the genomic variability within the *Candida* isolates ([@B24], [@B23]).

In the molecular typing of *C. albicans*, there were no strains that generated identical RAPD profiles, which may indicate an endogenous source of infection. These findings were in accordance with results obtained by da [@B8] who studied the genetic homology of 15 *C. albicans* strains using five primers. Similar results were found by [@B16] who used four primers for typing 42 *C. albicans* strains recovered from ICU patients. Furthermore, four *C. albicans* isolates cultured from various specimens from the same patients were determined to be different ([@B16]). In our study, the strains CA11 and CA12, isolated from the respiratory tract and urinary system of a single patient, were also unrelated. However, in some studies, *C. albicans* strains cultured from two sources from the same patient were genotypically identical. [@B6] typed 34 *C. albicans* strains that revealed the same RAPD patterns in blood samples and colonisation specimens collected from a single patient. [@B5] also observed that *C. albicans* strains recovered from different sites from a single patient were identical. Such results indicate the migration of yeasts from colonisation sites and confirm that previous colonisation is an important factor predisposing for systemic infection.

Molecular typing of 17 *C. glabrata* isolates revealed 16 different genotypes. We observed two strains generating identical RAPD profiles. Another study analysing the diversity of 19*C. glabrata* isolates originating from oral and vaginal specimens from Tunisia hospitals, revealed an even higher degree of genetic diversity among strains ([@B21]). Much lower genotypic variability of *C. glabrata* isolates, with two primers tested, was shown in a recent study from [@B12]. The investigation performed by [@B28] revealed 26 genotypes among 54 *C. glabrata* isolates, but it is noteworthy that the authors used only one primer in the study. Additionally, [@B9] observed a lower degree of genetic diversity among *C. glabrata* strains. The authors suggested that it is possible that primers used in the study were not appropriate for the typing of non-albicans species ([@B9]). Some authors highlighted that the strains classified as identical by one primer are not always classified as belonging to the same cluster when analysed by another primer ([@B5]). Therefore, the data obtained with a number of oligonucleotides should be combined to generate higher DP ([@B27]).

In the present study, we noticed a few groups of *C. albicans* and *C. glabrata* strains with similarity values between 80-99%, which represented related, but not identical clinical isolates. These findings may suggest microevolutionary changes of a single strain occurring during adaptation to environmental conditions ([@B27], [@B5]). Furthermore, there was the possibility that the unique strains presented in the dendrograms belonged to other species, such as *Candida africana* or *Candida bracarensis*, which are closely related to *C. albicans* and *C. glabrata*. However, these species can be distinguished only with molecular methods, including sequencing of the D1/D2 region of 26S rDNA ([@B29]).
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[^1]: *a: Candida lusitaniae, Candida lipolytica, Candida guilliermondii, Candida inconspicua, Saccharomyces cerevisiae, Geotrichum*sp.

[^2]: AMB: amphotericin B; CA1-CA31: *C. albicans*strains; CG1-CG17: *C. glabrata* strains; ETA: endotracheal aspirate; F: female; FLC: fluconazole; M: male; VRC: voriconazole; 5FC: 5-fluorocytosine.
